Fenwick Represents AnaptysBio in $100M Underwritten Registered Direct Offering

Fenwick represented AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, in its underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. The gross proceeds from this offering are expected to be approximately $100 million, before deducting underwriting discounts, commissions and other offering expenses payable by Anaptys.

The offering was led by current investor, EcoR1 Capital, and included participation from both new and existing investors, including Cormorant Asset Management, Farallon Capital Management, First Light Asset Management, Woodline Partners LP, multiple large investment management firms and Sanofi. More information can be obtained from AnaptysBio’s announcement.

The Fenwick team included corporate partners Effie Toshav and Ryan Mitteness and associates Leeza Soulina, Kate Pfeiffer and Sarah Marshall.